+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta subscript 46 and protecting Abeta from degradation



Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta subscript 46 and protecting Abeta from degradation



FASEB journal: official ication of the Federation of American Societies for Experimental Biology 20(2): 331-333




(PDF emailed within 1 workday: $29.90)

Accession: 015201018

Download citation: RISBibTeXText


Related references

Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation. Faseb Journal 20(2): 331-333, 2005

Calpain inhibitor MDL28170 modulates Ab formation by inhibiting the formation of intermediate Ab46 and protecting Ab from degradation. The FASEB Journal 20(2): 1-3, 2006

Human anti-Abeta antibodies block Abeta fibril formation and prevent Abeta-induced neurotoxicity. Neurology 60(5 Supplement 1): A69, March 11, 2003

The arctic mutation in the Abeta region of APP causes Alzheimers disease with increased Abeta protofibril formation and decreased Abeta peptide levels. Society for Neuroscience Abstracts 26(1-2): Abstract No -587 8, 2000

Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Molecular and Cellular Neurosciences 15(2): 183-198, 2000

p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. Journal of Neuroscience 31(6): 2292-2304, 2011

Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. Journal of Neuroscience 29(36): 11393-8, 2009

The relationship between Abeta-associated free radical generation and Abeta fibril formation. Society for Neuroscience Abstracts 27(1): 855, 2001

Static and dynamic AFM studies of the effect of anti-Abeta antibodies on Abeta aggregates and their formation. Biophysical Journal 86(1): 152a, January, 2004

Stabilities and conformations of Alzheimer's beta -amyloid peptide oligomers (Abeta 16-22, Abeta 16-35, and Abeta 10-35): Sequence effects. Proceedings of the National Academy of Sciences of the United States of America 99(22): 14126-14131, 2002

Protective effects of Abeta-derived tripeptide, Abeta(32-34), on Abeta(1-42)-induced phosphatidylinositol 4-kinase inhibition and neurotoxicity. Neuroscience Letters 419(3): 247-252, 2007

Abeta immmunization of PSAPP mice leads to decreased cerebral Abeta and a corresponding increase in serum Abeta. Society for Neuroscience Abstracts 27(2): 1807, 2001

Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Analytical Biochemistry 266(1): 66-76, 1999